ArticlePloS one2012
CD95 is part of a let-7/p53/miR-34 regulatory network.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Extracellular vesicles from induced pluripotent stem cell-derived periodontal ligament cells enhance proliferation and migration of periodontal ligament cells for periodontal regeneration.Frontiers in cell and developmental biology · 2026Article
- Expression of p53 in human adipose tissue correlates positively with FAS and BMI.International journal of obesity (2005) · 2025Article
- Article
- Repression of Irs2 by let-7 miRNAs is essential for homeostasis of the telencephalic neuroepithelium.The EMBO journal · 2020Article
- Multidimensional profiling of drug-treated cells by Imaging Mass Cytometry.FEBS open bio · 2019Article
- Survival of Naïve T Cells Requires the Expression of Let-7 miRNAs.Frontiers in immunology · 2019Article
- miR-20a Regulates FAS Expression in Osteosarcoma Cells by ModulatingMolecular cancer therapeutics · 2018Article
- MicroRNA-34 family in breast cancer: from research to therapeutic potential.Journal of Cancer · 2018Review
- The Hepatoprotective and MicroRNAs Downregulatory Effects of Crocin Following Hepatic Ischemia-Reperfusion Injury in Rats.Oxidative medicine and cellular longevity · 2017Article
- The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.Expert opinion on therapeutic targets · 2016Review
- microRNA regulators of apoptosis in cancer.Discoveries (Craiova, Romania) · 2016Review
- Article
- The role of CD95 and CD95 ligand in cancer.Cell death and differentiation · 2015Review
- Primary analysis and screening of microRNAs in gastric cancer side population cells.World journal of gastroenterology · 2015Article
- CD95 and CD95L promote and protect cancer stem cells.Nature communications · 2014Article
- Mir-34: a new weapon against cancer?Molecular therapy. Nucleic acids · 2014Review
- c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver.Molecular and cellular biology · 2014Article
- FAS-based cell depletion facilitates the selective isolation of mouse induced pluripotent stem cells.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The death receptor CD95 (APO-1/Fas) mediates apoptosis induction upon ligation by its cognate ligand CD95L. Two types of CD95 signaling pathways have been identified, which are characterized by the absence (Type I) or presence (Type II) of mitochondrial involvement. Micro(mi)RNAs are small noncoding RNAs that negatively regulate gene expression. They are important regulators of differentiation processes and are found frequently deregulated in many human cancers. We recently showed that Type I cells express less of the differentiation marker miRNA let-7 and, hence, likely represent more advanced tumor cells than the let-7 high expressing Type II cells. We have now identified miR-34a as a selective marker for cells that are sensitive to CD95-mediated apoptosis. Both CD95 and miR-34a are p53 target genes, and consequently, both the sensitivity of cancer cells to CD95-mediated apoptosis and the ability to respond to p53 mediated DNA genotoxic stress are linked. Interestingly, while miR-34a was found to positively correlate with the ability of cells to respond to genotoxic stress, let-7 was negatively correlated. The expression level of CD95 inversely correlated with the expression of let-7 suggesting regulation of let-7 expression by CD95. To test a link between p53 and miR-34a, we altered the expression of CD95. This affected the ability of cells to activate p53 and to regulate miR-34a. Our data point to a novel regulatory network comprising p53, CD95, let-7, and miR-34a that affects cancer cell survival, differentiation, and sensitivity to apoptotic signals. The possible relevance of this regulatory network for cancer stem cells is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.